Underexpressed CNDP2 Participates in Gastric Cancer Growth Inhibition through Activating the MAPK Signaling Pathway

Abstract

Increasing evidence suggests that cytosolic non-specific dipeptidase 2 (CNDP2) appears to do more than just perform an enzymatic activity; it is functionally important in cancers as well. Here, we show that the expression of CNDP2 is commonly downregulated in gastric cancer tissues. The ectopic expression of CNDP2 resulted in significant inhibition of cell proliferation, induction of cell apoptosis and cell cycle arrest, and suppressed gastric tumor growth in nude mice. We further revealed that the reintroduction of CNDP2 transcriptionally upregulated p38 and activated c-Jun NH 2 -terminal kinase (JNK), whereas the loss of CNDP2 increased the phosphorylation of extracellular signal-related kinase (ERK). These results suggest that CNDP2 acts as a functional tumor suppressor in gastric cancer via activation of the mitogen-activated protein kinase (MAPK) pathway.

Proteomic Profiling of HL-60 Cells during ATRA-Induced Differentiation

“…In 24 h after the start of differentiation, 9 unique differentially expressed proteins were revealed in the nucleus, including nucleotide exchange factor (BAG2), deubiquitinylation regulator (SHMT2), and Heat shock protein HSP 90-beta P08238 HSP90AB1 1.27×10 -8 Prothymosin alpha P06454 PTMA 2.56×10 -9 60S ribosomal protein L3 P39023 RPL3 1.10×10 -13 Eukaryotic translation initiation factor 3 subunit I Q13347 EIF3I 3.29×10 -9 Eukaryotic translation initiation factor 4 gamma 1 Q04637 EIF4G1 2.59×10 -10 Non-POU domain-containing octamer-binding protein Q15233 NONO 5.27×10 -9 S-adenosylmethionine synthase isoform type-2 P31153 MAT2A 2.82×10 -8 Elongation factor 2 P13639 EEF2 6.04×10 -10 Multifunctional protein ADE2 P22234 PAICS 6.39×10 -9 L-lactate dehydrogenase A chain P00338 LDHA 2.29×10 -8 Polypyrimidine tract-binding protein 1 P26599 PTBP1 4.10×10 -9 Glyceraldehyde-3-phosphate dehydrogenase P04406 GAPDH 1.04×10 -8 Elongation factor 1-beta P24534 EEF1B2 3.92×10 -8 Deoxyuridine MAPK signal pathway activator (CNDP2). The latter was shown to participate in the development of gastric cancer [27].…”

Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine

“…The classification according to the biological function of each oncogenic fusion transcript was done in regard to the literature (J. Fazal-Salom et al, 2017, Cancer Res., abstract). [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] Further, a patient with osteosarcoma (patient 17) was selected for validation of 3 potentially targetable fusions based on the presence of genes that, with their related pathways, are strongly linked to osteosarcoma biology (TP53-ZNF565, UBE4B-CTNNBIP1, and NF2-KIAA0368). These fusion transcripts had an oncoscore > 0.9, and, interestingly, they were found by three, two, or just one tool.…”

<p>Down-regulation of lncRNA LINC00152 Suppresses Gastric Cancer Cell Migration and Invasion Through Inhibition of the ERK/MAPK Signaling Pathway</p>

“…35 The MAPKs, regulated by Ras/Raf expression, have three main serine/threonine-related protein kinases, among which the ERK signaling pathway is especially correlated with cell survival, proliferation and differentiation and protecting cell against apoptosis. 36 It is reported that MAPK signaling can regulate many kinds of biological processes in cells, such as cell proliferation, apoptosis, differentiation, migration and invasion. 37,38 Abnormally expressed MAPK is proved to be related to tumorigenesis and metastatic potential for GC.…”